The study found that about 10% of people carry genetic variants linked to a phenomenon known as GLP-1 resistance. Individuals with these variants appear to produce higher levels of the hormone GLP-1 (glucagon-like peptide-1), which helps regulate blood sugar, yet the hormone does not seem to work as effectively in their bodies.

Researchers focused on blood sugar control and did not reach firm conclusions about weight loss effects. Drugs such as Ozempic and Wegovy are typically prescribed at higher doses for obesity treatment than for diabetes management, and more research is needed to determine whether the same genetic factors influence weight loss outcomes.

Published in Genome Medicine, the study brought together scientists from multiple countries over a period of 10 years. The work included experiments in both humans and mice, along with analyses of data from clinical trials involving diabetes medications.

“In some of the trials, we saw that individuals who had those variants were unable to lower their blood glucose levels as effectively after six months of treatment,” said Anna Gloyn, DPhil, professor of pediatrics and of genetics at Stanford Medicine and one of the study’s senior authors. At that stage, physicians would often consider changing a patient’s treatment plan. Identifying likely responders in advance could help patients reach the most effective therapy sooner and move diabetes care closer to precision medicine, she said.

The study’s other senior author is Markus Stoffel, MD, PhD, professor of metabolic diseases at the Institute of Molecular Health Sciences at ETH Zurich in Switzerland. Lead authors include Mahesh Umapathysivam, MBBS, DPhil, an endocrinologist and clinical researcher at Adelaide University in Australia and a former trainee with Gloyn, and Elisa Araldi, PhD, associate professor of medicine and surgery at the University of Parma in Italy and a former trainee with Stoffel.

“When I treat patients in the diabetes clinic, I see a huge variation in response to these GLP-1-based medications and it is difficult to predict this response clinically,” Umapathysivam said. “This is the first step in being able to use someone’s genetic make-up to help us improve that decision-making process.”

Scientists Investigate a Diabetes Drug Mystery

This research represents the first detailed examination of GLP-1 resistance, but scientists still do not know exactly what causes it.

“That is the million-dollar question,” Gloyn said. “We have ticked off this enormous list of all the ways in which we thought GLP-1 resistance might come about. No matter what we’ve done, we’ve not been able to nail precisely why they are resistant.”

The team concentrated on two genetic variants that reduce the activity of an enzyme called PAM (peptidyl-glycine alpha-amidating monooxygenase). This enzyme plays a unique role in the body because it activates a variety of hormones, including GLP-1.

“PAM is a truly fascinating enzyme because it’s the only enzyme we have that’s capable of a chemical process called amidation, which increases the half-life or the potency of biologically active peptides,” Gloyn said.

“We thought, if you have a problem with this enzyme, there’s going to be multiple aspects of your biology that are not working properly.”

Previous research had already shown that PAM variants occur more often in people with diabetes. Gloyn had also demonstrated that these variants impair the pancreas’s ability to release insulin. Researchers wanted to determine whether the same genetic changes also affected GLP-1, a hormone released from the gut that helps control blood sugar after eating by stimulating insulin production, slowing stomach emptying, and reducing appetite. GLP-1 receptor agonists work by mimicking this hormone.

An Unexpected Discovery About GLP-1 Levels

To investigate, researchers recruited adults with and without a PAM variant known as p.S539W. Participants drank a sugary solution, and blood samples were collected every five minutes over a four-hour period. The study involved people without diabetes to reduce the influence of other factors that could affect the results.

Scientists initially expected participants with the PAM variant to have lower levels of GLP-1 because the hormone might be less stable without proper amidation.

“What we actually saw was they had increased levels of GLP-1,” Gloyn said. “This was the opposite of what we imagined we would find.”

“Despite people with the PAM variant having higher circulating levels of GLP-1, we saw no evidence of higher biological activity. They were not reducing their blood sugar levels more quickly. More GLP-1 was needed to have the same biological effect, meaning they were resistant to GLP-1.”

Mouse Studies Confirm GLP-1 Resistance

The findings were so unexpected that the researchers spent several years testing whether the result was real.

“We couldn’t understand this, which is why we looked as many different ways as we could to see if this was a really robust observation,” Gloyn said.

To verify the findings, the team partnered with scientists in Zurich who had developed mice lacking the PAM gene. These animals displayed similar signs of GLP-1 resistance. They had elevated GLP-1 levels, yet the hormone was less effective at controlling blood sugar.

One of GLP-1’s major functions is slowing gastric emptying, which is the rate at which food leaves the stomach. This effect contributes to both blood sugar regulation and weight loss. Mice without the PAM gene showed faster gastric emptying, and treatment with a GLP-1 receptor agonist failed to slow the process.

Researchers also detected weaker responses to GLP-1 in both the pancreas and digestive tract of these mice. However, levels of GLP-1 receptors themselves remained unchanged.

Working with scientists in Copenhagen, the researchers further demonstrated that PAM defects do not interfere with GLP-1 binding to its receptor or with signaling at the receptor level. These findings suggest the source of GLP-1 resistance likely occurs farther downstream in the biological pathway.

Genetic Variants Affect Diabetes Drug Response

The team next examined whether GLP-1 resistance influenced real-world treatment outcomes.

Using data from three clinical trials that included 1,119 participants with diabetes, researchers found that people carrying PAM variants generally responded less well to GLP-1 receptor agonists. Their HbA1c levels, a measure of long-term blood sugar control, improved less than those of non-carriers.

After six months of treatment, approximately 25% of participants without the variants reached recommended HbA1c targets. Among carriers of the p.S539W variant, only 11.5% achieved those goals. For carriers of the p.D563G variant, the figure was 18.5%.

Importantly, the genetic variants did not appear to affect responses to several other common diabetes medications, including sulfonylureas, metformin, and DPP-4i drugs.

“What was really striking was that we saw no effect from whether you have a variant on your response to other types of diabetes medications,” Gloyn said. “We can see very clearly that this is specific to medications that are working through GLP-1 receptor pharmacology.”

Two additional pharmaceutical company-sponsored trials produced different results, with carriers and non-carriers responding similarly. Those studies involved longer-acting GLP-1 receptor agonists, which may be better able to overcome GLP-1 resistance, according to Gloyn.

Questions Remain About Weight Loss and Future Treatments

The research team first detected signs of GLP-1 resistance nearly a decade ago, long before GLP-1 drugs became widely known for weight loss.

Only two of the clinical trials included weight loss data. Those results showed no differences between people with and without PAM variants, but the available evidence was too limited to draw firm conclusions.

Gloyn noted that large amounts of genetic data from clinical trials likely already exist and could help answer important questions about why some people respond poorly to GLP-1 therapies.

“It’s very common for pharmaceutical companies to collect genetic data on their participants,” she said. “For the newer GLP-1 medications, it would be useful to look at whether there are genetic variants, like the variants in PAM, that explain poor responders to their medications.”

Although the biological mechanism remains unclear, Gloyn believes the answer is likely complex and influenced by multiple factors. She compares the situation to insulin resistance, which researchers still do not completely understand despite decades of study.

Even so, treatments have been developed to help overcome insulin resistance, raising the possibility that similar approaches could eventually be created for GLP-1 resistance.

“There are a whole class of medications that are insulin sensitizers, so perhaps we can develop medications that will allow people to be sensitized to GLP-1s or find formulations of GLP-1, like the longer-acting versions, that avoid the GLP-1 resistance.” she said.

Researchers from the University of Oxford, University of Dundee, University of Copenhagen, University of British Columbia, Churchill Hospital, Newcastle University, University of Bath, and University of Exeter also contributed to the study.

Funding was provided by Wellcome, the Medical Research Council, the European Union Horizon 2020 Program, the National Institutes of Health (grants U01-DK105535, U01-DK085545 and UM-1DK126185), the National Institute for Health Research Oxford Biomedical Research Centre, the Canadian Institutes of Health Research, the Novo Nordisk Foundation, Boehringer Ingelheim, and Diabetes Australia.

These giant black hole duos are expected to form naturally after galaxies merge. Although astronomers have identified some widely separated supermassive black hole pairs, finding those that orbit much closer together has proven far more difficult.

In a study published in Physical Review Letters, the researchers suggest searching for a distinctive signal. As the black holes orbit each other, their immense gravity could repeatedly magnify the light from stars located behind them, creating recurring flashes that may reveal the hidden systems.

Galaxy Mergers Create Supermassive Black Hole Binaries

Most galaxies contain a supermassive black hole at their center. When galaxies collide and eventually combine, their central black holes can become gravitationally bound, forming what scientists call a supermassive black hole binary.

These systems are important for understanding how galaxies evolve over time. They are also expected to generate some of the strongest gravitational waves in the universe.

Future space-based gravitational wave observatories should be able to detect these binaries directly. However, the new research suggests that astronomers may not have to wait. Existing and upcoming sky surveys could potentially identify them through their effects on visible light.

“Supermassive black holes act as natural telescopes,” said Dr. Miguel Zumalacárregui from the Max Planck Institute for Gravitational Physics. “Because of their enormous mass and compact size, they strongly bend passing light. Starlight from the same host galaxy can be focused into extraordinarily bright images, a phenomenon known as gravitational lensing.”

How Gravitational Lensing Creates Bright Flashes

A single supermassive black hole can dramatically magnify a background star, but only when the alignment is almost perfect.

A binary system behaves differently. With two black holes acting as gravitational lenses, the region where extreme magnification can occur becomes much larger. The pair creates a diamond-shaped feature known as a caustic curve, where stars can appear dramatically brighter.

In theory, a perfectly point-like star could be magnified infinitely. In reality, the finite size of stars places a limit on how bright the effect can become.

“The chances of starlight being hugely amplified increase enormously for a binary compared to a single black hole,” said Professor Bence Kocsis from the University of Oxford’s Department of Physics and a co-author of the study.

Repeating Stellar Flashes Could Reveal Hidden Black Holes

Unlike a single black hole, a black hole binary is constantly changing.

As the two black holes orbit each other, they gradually lose energy through the emission of gravitational waves, a process predicted by Einstein’s theory of general relativity. Over time, this causes the black holes to move closer together and orbit faster.

Graduate student Hanxi Wang is in Professor Kocsis’ group and led the study: “As the binary moves, the caustic curve rotates and changes shape, sweeping across a large volume of stars behind it. If a bright star lies within this region, it can produce an extraordinarily bright flash each time the caustic passes over it. This leads to repeating bursts of starlight, which provide a clear and distinctive signature of a supermassive black hole binary.”

Because the caustic structure continually shifts, the resulting flashes would occur again and again, creating a recognizable pattern that astronomers could search for.

Clues About Black Hole Masses and Orbits

The team found that the timing and intensity of these flashes should follow predictable trends rather than appearing randomly.

As gravitational waves slowly shrink the orbit, they subtly alter the shape and motion of the caustic curve. Those changes leave measurable signatures in both the brightness and frequency of the flashes.

By analyzing these patterns, researchers could estimate important characteristics of the hidden binary, including the masses of the black holes and details of their orbital evolution.

Powerful new observatories, including the Vera C. Rubin Observatory and the Nancy Grace Roman Space Telescope, are expected to dramatically expand the search for these repeating lensing events in the coming years.

“The prospect of identifying inspiraling supermassive black hole binaries years before future space-based gravitational wave detectors come online is extremely exciting,” concludes Professor Kocsis. “It opens the door to true multi-messenger studies of black holes, allowing us to test gravity and black hole physics in entirely new ways.”

Burning the oil, a technique known as an in situ burn, can prevent the slick from expanding. However, it also produces thick clouds of black smoke, releases soot into the atmosphere, and leaves behind a layer of unburned residue floating on the ocean’s surface.

Now, researchers have demonstrated a striking new approach that could make this process far more effective. In a first-of-its-kind large-scale study, scientists created giant fire whirls, spinning columns of flame that resemble fire tornadoes, and found they burn oil faster and more cleanly than conventional methods.

The rotating vortex draws in large amounts of oxygen, creating a hotter and more efficient flame. As a result, the fire whirl consumed oil more rapidly while producing significantly less pollution.

The study, supported by the Bureau of Safety and Environmental Enforcement (BSEE), was led by Dr. Elaine Oran and Dr. Qingsheng Wang of Texas A&M University and Dr. Michael Gollner of the University of California, Berkeley.

“This the first time anyone has conceived using fire whirls for oil spill remediation, and it’s really just the beginning,” said Oran, professor of aerospace engineering in the College of Engineering. “Our goal is to harness the chaotic nature of fire whirls as a powerful, precise restoration tool, to protect coastlines, marine ecosystems and the environment as a whole.”

A Faster, Cleaner Way to Fight Oil Spills

The research introduces an unconventional strategy for dealing with one of the most damaging environmental emergencies.

The devastating Deepwater Horizon disaster in 2010 remains a powerful reminder of the impact offshore oil spills can have. The accident, the largest offshore oil spill in U.S. history, killed 11 workers, claimed the lives of thousands of marine animals, and caused widespread damage to ocean ecosystems.

“We are looking at environmental disasters like oil spills, and identifying ways to remediate them in faster, greener and more sustainable ways,” Oran said.

One of the most promising advantages of fire whirls is speed.

According to the researchers, fire whirls can burn crude oil nearly twice as fast as traditional in situ fire pools. Faster removal of oil could give response teams a critical advantage, allowing them to eliminate spills before they spread into sensitive habitats and protected coastal regions.

“Fire whirls burn through crude oil spills nearly twice as fast as in-situ fire pools, potentially giving cleanup crews faster operational and response times to eliminating the oils from spreading,” Oran said.

The technique could also reduce one of the biggest drawbacks of burning oil: smoke.

“One of the biggest challenges of burning oil spills is the sheer volume of smoke emitted,” Oran said. “Our results show that fire whirls, compared to in-situ fires, dramatically reduce overall emissions.”

Acting like a giant incinerator, the spinning flames destroy many of the particles responsible for dense smoke plumes. The process also vaporizes most of the oil before it can remain behind as a toxic tar-like residue on the water.

The findings may have applications beyond oil spill response. A better understanding of how fire whirls form and behave could help engineers develop more efficient combustion systems and improve efforts to predict and manage wildfires.

“Our study has universal applications,” Oran said. “By understanding the physical laws that govern fire whirls, we can harness their power beyond oil spill remediation.”

Building a 17-Foot-Tall Fire Whirl

Most previous studies of fire whirls have been conducted on a much smaller scale in laboratory settings.

To explore whether the phenomenon could be useful for real-world oil spill cleanup, the research team designed an experiment large enough to mimic more realistic conditions.

“The scale of our experiment is one of the reasons why our investigation is so unique, and what sets it apart as a first-of-its-kind,” Oran said.

The researchers built a 16-foot-tall triangular structure with three walls that allowed them to carefully control airflow. At the center, they placed a 1.5-meter-wide pool of crude oil floating on water.

Once ignited at the Texas A&M Engineering Extension Service (TEEX) Brayton Fire Training Field, the setup generated a powerful fire whirl that reached nearly 17 feet in height.

The results, published in Fuel, showed major improvements over conventional oil burning techniques.

“The fire whirls burned the oil about 40 percent faster, cut soot emissions by 40 percent, and achieved up to 95 percent fuel consumption efficiency compared to in-situ fire tests,” Oran said.

Finding the Fire Whirl “Goldilocks” Zone

Despite their impressive performance, fire whirls are not easy to control.

“Fire whirls are incredibly powerful, and can be incredibly beneficial,” Oran said. “But they’re also sensitive and only reach high efficiency when the conditions are just right.”

Strong winds can destabilize the spinning column or cause it to collapse altogether. Insufficient airflow control can prevent the vortex from forming, causing the fire to behave more like a conventional burn.

Researchers also discovered that the thickness of the oil layer plays an important role. When the slick became too deep, the fire whirls went out before consuming all of the fuel.

This narrow range of ideal conditions, described by the researchers as a “Goldilocks” zone, highlights both the promise and the challenge of bringing the technology into practical use.

Fire Tornadoes as Future Cleanup Tools

The team envisions a future in which portable systems could be deployed directly over burning oil spills to intentionally generate fire whirls on demand.

If successful, such systems could transform emergency oil spill response by converting ordinary fires into highly efficient cleanup tools.

“This study is more than just an experiment, it’s a glimpse into a future where fire isn’t a force of destruction, but a tool to protect our oceans and planet,” Oran said.

For now, the research stands as an impressive demonstration of what can happen when scientists rethink a familiar natural phenomenon.

It suggests that even one of nature’s most intimidating forces can potentially be redirected to address some of the world’s most urgent environmental challenges.

Although much of the salt people consume comes from processed and prepared foods, adding salt at the table still contributes between 6% and 20% of total intake. Researchers know that this habit varies among different groups of people, but it has not always been clear who is most likely to reach for the saltshaker in different cultural settings.

A new study published in Frontiers in Public Health sought to answer that question among older adults in Brazil.

“Adding salt to food at the table remains a relatively common habit among Brazilian older adults and occurs more frequently among men than among women,” said first author Dr. Flávia Brito, an associate professor at Rio de Janeiro State University.

“Women’s salt-adding behavior, however, was associated with a wider range of social and dietary characteristics than men’s,” added co-author Dr. Débora Santos, a titular professor at Rio de Janeiro State University.

Who Is Most Likely To Add Extra Salt?

The researchers analyzed survey data collected between 2016 and 2017 from more than 8,300 Brazilians aged 60 and older. Participants reported everything they had eaten and drunk during the previous 24 hours and answered whether they routinely added salt to food at the table.

The team also examined several factors that could influence this behavior, including sex, age, education level, household income, living arrangements, urban or rural residence, and whether participants regularly consumed fruits, vegetables, or ultra-processed foods.

The results showed that 12.7% of men reported adding extra salt to their meals, compared with 9.4% of women. However, the factors linked to this habit differed significantly between the sexes.

“Among men, few variables were associated with the habit of adding salt, suggesting that their behavior may be less directly related to specific dietary patterns,” Brito pointed out.

“On the other hand, women’s salt-adding behavior appeared to be more closely linked to broader dietary patterns and contextual characteristics,” added Santos.

Lifestyle and Diet Influence Salt Habits

Among men, only two factors were significantly connected to adding extra salt. Men following a special diet to manage high blood pressure were less than half as likely to add salt compared with those who were not following such a diet. Men who lived alone were 62% more likely to add salt than those living with other people.

Women showed a more complex pattern. Those who were not following a diet for high blood pressure had 68% higher odds of adding extra salt. Women living in urban areas were twice as likely to do so, and the same increase was observed among women who frequently consumed ultra-processed foods.

By contrast, women who regularly ate fruits were 81% less likely to add salt, while those who commonly consumed vegetables were 40% less likely to do so. According to the researchers, these findings may reflect greater attention to overall diet quality, including efforts to limit salt intake.

Why Do People Reach for the Saltshaker?

The researchers emphasized that the study does not establish cause-and-effect relationships. Because participants self-reported their habits, some responses may have been inaccurate. The authors also noted that salt-use patterns may have changed since the surveys were conducted.

According to the team, both taste preferences and long-standing habits may drive the urge to add salt. Regular consumption of high-sodium foods can reduce sensitivity to salty flavors, leading some people to prefer stronger levels of saltiness. In many cases, however, adding salt may simply be a routine behavior rather than a response to taste.

Reducing overall salt consumption will likely require efforts beyond individual choices. The researchers pointed to the need for lower sodium levels in industrialized and ultra-processed foods, which are major contributors to excessive salt intake.

At the same time, individuals can take practical steps to reduce their own salt use. Because the factors associated with salt-adding behavior differed between men and women, the researchers suggest that public health campaigns should be tailored to specific groups based on gender and lifestyle characteristics.

“The use of herbs and natural seasonings as alternatives to salt or culinary techniques such as using the acidity of citrus fruits may help reduce discretionary salt use while maintaining food palatability,” concluded Santos. “Practical strategies, such as avoiding the routine placement of saltshakers on the table, may also help reduce habitual salt use.”

Pancreatic cancer is so deadly in part because there are no effective screening tests, and it rarely causes noticeable symptoms in its earliest stages. By the time a patient experiences signs, such as jaundice – a yellowing of the skin – or abdominal pain, the cancer has often already spread to other organs.

As a gastrointestinal oncologist and researcher specializing in early-phase clinical trials, I have seen the critical need for more effective therapies for patients with pancreatic cancer. For decades, successfully targeting the central mechanism that causes the vast majority of pancreatic cancers was considered impossible.

However, that narrative is rapidly changing with a new drug that can shut down the key protein that drives pancreatic cancer, nearly doubling survival rates for patients with advanced stages of the disease.

‘Undruggable’ tumors

The standard treatment for advanced pancreatic cancer has historically relied on chemotherapy, potent drugs designed to kill rapidly dividing cells. While chemotherapy can slow the progression of the disease, its effectiveness is often limited by the ability of pancreatic cancer cells to develop resistance against these drugs.

Pancreatic cancer’s success lies in its genetics. More than 90% of pancreatic tumors are driven by mutations in a gene called KRAS. This gene codes for proteins that function as switches that turn cell growth on and off. When the KRAS gene is mutated, the switch becomes permanently stuck in the “on” position, commanding cancer cells to multiply endlessly.

For decades, scientists considered KRAS to be “undruggable.” The surface of the protein is exceptionally smooth, lacking the molecular pockets that standard drugs require to bind to and turn the switch off.

Because existing drugs haven’t been able to target this protein, treatment for pancreatic cancer has primarily relied on toxic drugs that act more like blunt instruments than precise tools. Chemotherapy attempts to control the disease through widespread cell destruction, causing significant collateral damage to healthy tissues that lead to side effects.

What is daraxonrasib?

A new drug called daraxonrasib offers a critical advance in treating metastatic pancreatic cancer.

Daraxonrasib is taken daily by mouth. Instead of binding to KRAS directly, it attaches to a molecule called cyclophilin A in cells that helps fold proteins into their final 3D structures. This protein complex is then able to bind to the active KRAS protein and shut down its ability to signal cancer cells to multiply.

The company developing the drug, Revolution Medicines, presented results on May 31, 2026, from its Phase 3 clinical trial of 500 patients with metastatic pancreatic cancer who had received prior treatment. Compared to standard chemotherapy, daraxonrasib nearly doubled overall survival from 6.7 months to 13.2 months after diagnosis. Overall, daraxonrasib reduced the risk of death for metastatic pancreatic cancer patients by 60%.

The most common side effect is a prominent skin rash, which affected more than 86% of patients in the study. Patients also frequently dealt with stomatitis – painful swelling and sores inside the mouth – as well as diarrhea, nausea and vomiting. However, patients taking daraxonrasib were far less likely to stop treatment due to severe side effects compared to chemotherapy, and they had improved quality of life with reduced pain.

Next steps for daraxonrasib

By successfully targeting the specific genetic mutation that drives the vast majority of pancreatic cancers, researchers have demonstrated that this “undruggable” disease is treatable with targeted therapy.

The immediate next step is regulatory review of the drug’s readiness for the clinic. With data now officially published, Revolution Medicines will use these findings to seek formal approval from the Food and Drug Administration and other global regulatory bodies.

Because advanced pancreatic cancer is notoriously difficult to treat, breakthrough therapies that demonstrate this kind of significant survival benefit are often granted expedited or priority review. When daroxonrasib becomes available to patients will depend on the review timeline. Should the drug obtain approval, it could be available in clinics within months.

For the broader landscape of drug development, this milestone represents a likely shift in pancreatic cancer treatment. I expect more clinical trials exploring combination therapies pairing KRAS inhibitors with other drugs to prevent tumors from developing resistance to treatment.

Should daraxonrasib succeed, it could help set the stage for more precise, personalized and effective treatments for pancreatic cancer in the years to come.

Goethe’s amber collection, now housed at the Goethe National Museum and managed by the Klassik Stiftung Weimar, contains 40 pieces of Baltic amber. Two of those specimens turned out to contain fossilized animals that were nearly impossible to see with the naked eye because the amber pieces were never polished.

To investigate further, researchers from the University of Jena turned to modern scanning techniques. At the German Electron Synchrotron (DESY) in Hamburg, they used synchrotron micro computed tomography to create detailed three dimensional images of the fossils. The scans revealed three insects: a fungus gnat, a black fly, and an ancient ant.

Ancient Ant Reveals New Details

Among the discoveries, the ant attracted the most attention.

“The ant belongs to the extinct species †Ctenobethylus goepperti (Mayr, 1868), which is very common in amber,” explains Bernhard Bock from the Phyletisches Museum of the University of Jena. “Thanks to its excellent preservation and the extensive investigations, however, we were able to describe it in greater detail than ever before and gain new information about the species and its relationships.”

Because the specimen is so exceptionally preserved, scientists were able to examine features that had never been documented in such detail. The scans revealed fine body hairs on the worker ant and even allowed researchers to visualize internal skeletal structures within the head and thorax. These observations provide valuable new information about the anatomy and evolution of the species.

The research team also produced a complete digital reconstruction of the fossil.

“We have fully processed the specimen and, based on the newly acquired information, created a 3D reconstruction that is available online,” says Daniel Tröger from the University of Jena. “This model helps colleagues worldwide to identify and compare further fossils of this species.”

Comparisons with the modern ant genus Liometopum, which is found today in North America and warmer parts of Europe, offer clues about how the extinct species may have lived. Researchers believe the ancient ants likely built large nests in trees, which may help explain why they are so commonly preserved in amber.

Goethe’s Connection to Amber

Although Goethe owned the amber specimens, he showed relatively little interest in amber itself beyond its optical properties. He even ground lenses from fossilized resin to study color effects as part of his work on color theory.

By Goethe’s time, scientists had already begun studying amber and the fossils preserved inside it. Early scientific publications on the subject were available in his personal library. However, the broader scientific importance of these fossils had not yet become clear, and the discoveries being made today were far beyond what researchers of that era could have imagined.

“Goethe is regarded as the founder of morphology and would likely have been delighted to see how we were able to gain valuable insights in this field using entirely new methods,” says Bernhard Bock. “At the same time, the results demonstrate the value of such historical collections. It is truly fascinating that an object originating from his hand and his era, when this science was just beginning, can still enrich us so much today.”

The findings highlight how museum collections assembled centuries ago can continue to yield important scientific discoveries. Thanks to modern imaging techniques, objects that once seemed ordinary can still reveal hidden stories from Earth’s distant past.